|
Volumn 38, Issue SUPPL. 1, 2005, Pages
|
Topic IV: Hormonal influence on treatment and the effect of treatments on contraceptive methods, continued - Data from the United States Food and Drug Administration
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMPRENAVIR;
ANTIRETROVIRUS AGENT;
CYTOCHROME P450 2B6;
CYTOCHROME P450 3A4;
EFAVIRENZ;
ESTROGEN;
ETHINYLESTRADIOL;
FLUCONAZOLE;
FOLLITROPIN;
GESTAGEN;
GESTODENE;
GLUCURONOSYLTRANSFERASE;
INDINAVIR;
LEVONORGESTREL;
LOPINAVIR PLUS RITONAVIR;
LUTEINIZING HORMONE;
NELFINAVIR;
NEVIRAPINE;
NORETHISTERONE;
ORAL CONTRACEPTIVE AGENT;
PROGESTERONE;
PROTEINASE INHIBITOR;
RIFABUTIN;
RIFAMPICIN;
RITONAVIR;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
SEX HORMONE BINDING GLOBULIN;
ADULT;
AREA UNDER THE CURVE;
BREAKTHROUGH BLEEDING;
CARDIOVASCULAR DISEASE;
CONFERENCE PAPER;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG METABOLISM;
FEMALE;
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
HYPOLIPOPROTEINEMIA;
INSULIN RESISTANCE;
LIVER ADENOMA;
NONHUMAN;
PRIORITY JOURNAL;
RAT;
SIDE EFFECT;
UNITED STATES;
WORLD HEALTH ORGANIZATION;
|
EID: 18244373969
PISSN: 15254135
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
Times cited : (1)
|
References (16)
|